Singapore markets close in 16 minutes

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
107.08+0.44 (+0.41%)
At close: 04:00PM EST
107.63 +0.55 (+0.51%)
After hours: 07:54PM EST
Sign in to post a message.
  • B
    BetsyB
    Wegovy is an amazing weight loss drug - huge future ahead as more insurance plans add it to their formulary. It works differently than weight loss drugs in the past (slows digestive system and simulates a hormone that makes you feel fuller). I am on a Wegovy support group page and the feedback and results are amazing.
  • a
    ageninrussia
    Novo Nordisk to buy RNAi therapy developer Dicerna for $3.3 billion $NVO $DRNA
  • h
    henry
    Earnings leak in Denmark, even better than last Fridays news. Thats why its up AH
  • A
    Adrian
    A couple of months ago a very intelligent friend of mine told me to buy NVO and $NVDA. So glad I listened to him. Up 28% already!...He also told me to hold don’t sell. That’s exactly what I will do
  • A
    Alexander
    This is a great company, product line, and the stock is reallying showing it.
  • h
    henry
    $120 by Christmas? with all the good news from the ER and a little profit taking this should start marching towards $120. Plus the EU news that just came out on Friday
  • Y
    Yahoo Finance Insights
    NVO reached an all time high at 109.42
  • R
    Rayme
    Novo Nordisk returns to strong growth after 7 years.
  • r
    ram
    It seems the SP is overly inflated. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide. All may not use this product and side effects will be there.
    There will be a correction to SP which will bring down to some extent.
  • D
    DC
    NVO bought EMIS for 1 reason to turn injectables into once daily pill. Wegovy is next on the list. This will be a multi billion dollar product.
  • A
    Adrian
    I’m expecting $150 or a Split. Either one Okay with me! $NVO🚀
  • h
    henry
    Going over $110 after earnings on Nov 3rd
  • B
    BetsyB
    Not only is Wegovy so popular that they ran out of supply, Wegovy WORKS. A huge future ahead.
  • F
    Freedom
    $MRK conversation
    MPLN as per yahoo 92% shares are owned by institutes.

    $PEF $NVO $CVC $GILD
  • R
    Rayme
    NVO will be extremely profitable for many more years because they will get at least 3-4 indications with one semaglutide molecule with two methods of delivery oral and once weekly injectable. The semaglutide franchise is expected to generate over $4-5 billion in annual sales within the next 3 years.
  • p
    peachbacks
    Wegovy will be a common brand name. MY concern is Lilly taking market share yet they will increase the market.
  • C
    C
    CONFIRMED breakout above 107.61, no resistance in area just above.
    Type: True breakout from double resistance.
    Target: 113.67
  • b
    blackoutbuzz
    Currently trading at ~610DKK

    @@@09/28/2021 | 03:34am EDT In a research note published by Richard Vosser, JP Morgan advises its customers to buy the stock. The target price is still set at DKK 700.
  • B
    Bjarne
    Wow wow wow!
  • C
    C
    NVO is due for a split. Historically, NVO has split about every 7 years near current price levels. Previous split dates:
    January 9, 2014 5:1
    December 17, 2007 2:1
    April 11, 2001 5:2
    April 18, 1994 4:1